Isolation of a Second Recombinant Human Respiratory Syncytial Virus Monoclonal Antibody Fragment (Fab RSVF2–5) that Exhibits Therapeutic Efficacy In Vivo | Zendy

James E. Crowe | Zendy; Peter S. Gilmour | Zendy; Brian R. Murphy | Zendy; Robert M. Chanock | Zendy; Lingxun Duan | Zendy; Roger J. Pomerantz | Zendy; Glenn Pilkington | Zendy

Open Access

Isolation of a Second Recombinant Human Respiratory Syncytial Virus Monoclonal Antibody Fragment (Fab RSVF2–5) that Exhibits Therapeutic Efficacy In Vivo

Author(s) -

James E. Crowe,

Peter S. Gilmour,

Brian R. Murphy,

Robert M. Chanock,

Lingxun Duan,

Roger J. Pomerantz,

Glenn Pilkington

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/517397

Subject(s) - monoclonal antibody , virology , recombinant dna , in vivo , antibody , isolation (microbiology) , virus , biology , monoclonal , fragment (logic) , paramyxoviridae , mononegavirales , immunology , microbiology and biotechnology , viral disease , biochemistry , gene , computer science , programming language

A second human respiratory syncytial virus (RSV)-neutralizing monoclonal antibody was isolated and its binding site was identified. Fab F2-5 is a broadly reactive fusion (F) protein-specific recombinant Fab generated by antigen selection from a random combinatorial library displayed on the surface of filamentous phage. In an in vitro plaque-reduction test, the Fab RSVF2-5 neutralized the infectivity of a variety of field isolates representing viruses of both RSV subgroups A and B. The Fab recognized an antigenic determinant that differed from the only other human anti-F monoclonal antibody (RSV Fab 19) described thus far. A single dose of 4.0 mg of Fab RSVF2-5/kg of body weight administered by inhalation was sufficient to achieve a 2000-fold reduction in pulmonary virus titer in RSV-infected mice. The antigen-binding domain of Fab RSVF2-5 offers promise as part of a prophylactic regimen for RSV infection in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research